Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Apr 15;26(8):1894-900.
doi: 10.1016/j.bmcl.2016.03.026. Epub 2016 Mar 9.

N-Alkylpyrido[1',2':1,5]pyrazolo-[4,3-d]pyrimidin-4-amines: A new series of negative allosteric modulators of mGlu1/5 with CNS exposure in rodents

Affiliations

N-Alkylpyrido[1',2':1,5]pyrazolo-[4,3-d]pyrimidin-4-amines: A new series of negative allosteric modulators of mGlu1/5 with CNS exposure in rodents

Andrew S Felts et al. Bioorg Med Chem Lett. .

Abstract

Selective negative allosteric modulators (NAMs) of each of the group I metabotropic glutamate receptors (mGlu1 and mGlu5) have been well characterized in the literature and offer potential as therapeutics in several disorders of the central nervous system (CNS). Still, compounds that are potent mGlu1/5 NAMs with selectivity versus the other six members of the mGlu family as well as the balance of properties required for use in vivo are lacking. A medicinal chemistry effort centered on the identification of a lead series with the potential of delivering such compounds is described in this Letter. Specifically, a new class of pyrido[1',2':1,5]pyrazolo[4,3-d]pyrimidin-4-amines was designed as a novel isosteric replacement for 4-aminoquinazolines, and compounds from within this chemotype exhibited dual NAM activity at both group I mGlus. One compound, VU0467558 (29), demonstrated near equipotent activity at both receptors, selectivity versus other mGlus, a favorable ancillary pharmacology profile, and CNS exposure in rodents.

Keywords: Central nervous system (CNS); G-protein coupled receptor (GPCR); Metabotropic glutamate receptor subtype 1 (mGlu(1)); Metabotropic glutamate receptor subtype 5 (mGlu(5)); Negative allosteric modulator (NAM).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Quinazoline and quinazoline-like group I mGlu NAMs
Figure 2
Figure 2
Proposal for development of novel mGlu1/5 NAMs from a pyrido[1′,2′:1,5]pyrazolo[4,3-d]pyrimidin-4-amine scaffold
Scheme 1
Scheme 1
Reagents and conditions: (a) Reagents and conditions: (a) KNO3, H2SO4, 0 °C to r.t., 79%; (b) SnCl2, con. HCl, dioxane, 65%; (c) For R1 = H, HCONH2, microwave, 200 °C, 60 min., 98%; (d) For R1 = CH3, CH3C(OEt)3, formic acid, microwave, 180 °C, 60 min., 24%; (e) POCl3, microwave, 140 °C, 20 min., 59% (R1 = H), 54% (R1 = CH3); (f) R2NH2, DIEA, DMF, microwave, 150 °C, 15 min., 43-84%.
Scheme 2
Scheme 2
Reagents and conditions: (a) (i) ClCO2Et, dioxane 100 °C, 16 h, (ii) KOtBu, isopropanol, microwave, 160 °C, 15 min., 99%; (b) POCl3, microwave, 140 °C, 20 min., 84%; (c) trans-4-methylcyclohexylamine, DIEA, DMF, rt, 16h., 76%; (d) R3NH2, DIEA, DMF, microwave, 150 °C, 10 min., 48-77%.

References

    1. Niswender CM, Conn PJ. Annu. Rev. Pharmacol. Toxicol. 2010;50:295. - PMC - PubMed
    1. Schoepp DD, Jane DE, Monn JA. Neuropharmacology. 1999;38:1431. - PubMed
    1. Conn PJ, Pin J-P. Annu. Rev. Pharmacol. Toxicol. 1997;37:205. - PubMed
    1. Melancon BJ, Hopkins CR, Wood MR, Emmitte KA, Niswender CM, Christopoulos A, Conn PJ, Lindsley CW. J. Med. Chem. 2012;55:1445. - PMC - PubMed
    1. Conn PJ, Christopolous A, Lindsley CW. Nat. Rev. Drug Discovery. 2009;8:41. - PMC - PubMed

Publication types

LinkOut - more resources